

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5174073

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TOM HUYSMANS	06/25/2018
TARRYN DIERCKX	09/25/2018
STEFAN JAAK VANQUICKENBORNE	06/25/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CAPSUGEL BELGIUM NV
<b>Street Address:</b>	RIJKSWEG 11
<b>City:</b>	BORNEM
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	2880
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
PCT Number:	EP2016068842
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	503-595-5300
<b>Email:</b>	erin.vaughn@klarquist.com
<b>Correspondent Name:</b>	LISA M. CALDWELL, KLARQUIST SPARKMAN LLP
<b>Address Line 1:</b>	121 SW SALMON ST., STE. 1600
<b>Address Line 2:</b>	ONE WORLD TRADE CENTER
<b>Address Line 4:</b>	PORTLAND, OREGON 97204-2927
<b>ATTORNEY DOCKET NUMBER:</b>	9156-97767-02
<b>NAME OF SUBMITTER:</b>	LISA M. CALDWELL
<b>SIGNATURE:</b>	/Lisa M. Caldwell/
<b>DATE SIGNED:</b>	10/04/2018
<b>Total Attachments: 4</b>	
source=9156-97767-02_Assignment#page1.tif	
source=9156-97767-02_Assignment#page2.tif	
source=9156-97767-02_Assignment#page3.tif	



ASSIGNMENT

WHEREAS, we, Tom Huysmans, of Sint-Niklaas, Belgium, Tarryn Dierckx, of Deurne, Belgium and Stefaan Jaak Vanquickenborne, of Rijnmenam, Belgium, have invented a certain invention, which invention is at least partially disclosed in the following patent applications:

European Patent Application No. 15194821.3, filed on November 10, 2015, entitled  
"TAMPERPROOF ORAL DOSAGE FORM,"

PCT Patent Application No. PCT/EP2016/068842, filed on August 8, 2016, entitled  
"TAMPERPROOF ORAL DOSAGE FORM,"

U.S. Patent Application No. 15/759,381, filed on April 19, 2018, entitled "TAMPERPROOF ORAL  
DOSAGE FORM,"

which the invention and applications collectively referred to hereinafter as "the Invention,"

WHEREAS, Capsugel Belgium NV, a corporation organized under the laws of Belgium, having a place of business at Rijksweg 11, 2880 Bornem, Belgium, desires to acquire an interest therein:


NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, we, Tom Huysmans, Tarryn Dierckx and Stefaan Jaak Vanquickenborne hereby sell, assign, and transfer to Capsugel Belgium NV, the full and exclusive right, title, and interest in and to the Invention, the patent applications, and patent rights throughout the world, including foreign patent priority rights, the right to file and prosecute International Applications under the Patent Cooperation Treaty, and the right to file and prosecute applications under the European Patent Convention; the Invention, the patent applications, and letters patent in this or any foreign country, and all corresponding non-provisional applications, divisions, continuations, continuations-in-part, reissues, and extensions thereof, to be held and enjoyed by Capsugel Belgium NV, for its own use and benefit, and for its successors and assigns to the full end of the term for which letters patent may be granted by the United States or any foreign country, as fully and entirely as the same would have been held by us had this assignment and sale not been made, and covenant that we have full right so to do, and agree that we will communicate to Capsugel Belgium NV, or its successors and assigns, any facts known to us respecting the Invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, and reissue applications, make all rightful oaths, and do everything possible to aid Capsugel Belgium NV, its successors, and assigns to obtain and enforce proper patent protection for the Invention in the United States or any foreign country.


We confirm that, at the time the invention was made, we were under an obligation to assign the invention to Capsugel Belgium NV.


We hereby grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Assignment any further information that may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.

Executed on the date opposite our respective signatures below.

Date: 25/06/2018

  
\_\_\_\_\_  
Tom Huysmans

Witnessed:  
Signature:   
Name: A. Tenter

Witnessed:  
Signature:   
Name: H. Brands

9168-97787-02 LP2779LUSPC00


Date: 25 September 2018


T. Dierckx  
Tarryn Dierckx


Witnessed:  
Signature: [Signature]  
Name: A. Tenoniel

Witnessed:  
Signature: [Signature]  
Name: u. O. de...

Date: 25 June 2018

  
Stefaan Jaak Vanquickenborne

Witnessed:  
Signature:   
Name: A. Tenique

Witnessed:  
Signature:   
Name: W. Bando